SCSrijita Paul Chowdhuri

Srijita Paul Chowdhuri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Srijita Paul Chowdhuri has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Benu Brata Das

    Laboratory of Molecular Biology, School of Biological Sciences, Indian Association for the Cultivation of Science, 2A & B, Raja S. C. Mullick Road, Jadavpur, Kolkata 700032, India

    5 shared publications
  • Arijit Ghosh

    Laboratory of Molecular Biology, School of Biological Sciences ; Indian Association for the Cultivation of Science , 2A & 2B, Raja S. C. Mullick Road , Kolkata , 700032 West Bengal , India

    3 shared publications
  • Arindam Talukdar

    Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata 700032, WB, India

    2 shared publications
  • Dipayan Sarkar

    CSIR- Indian Institute of Chemical Biology, Organic and Medicinal Chemistry Division, West Bengal, Kolkata, 700032, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India

    2 shared publications
  • Ishita Rehman

    Laboratory of Molecular Biology, School of Biological Sciences, Indian Association for the Cultivation of Science, 2A & B, Raja S. C. Mullick Road, Jadavpur, Kolkata 700032, India

    2 shared publications
  • Sourav Pal

    Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata, 700032, WB, India; Academy of Scientific and Innovative Research, Ghaziabad, 201002, India

    2 shared publications

Latest Publications

  • Development of a metabolically stable topoisomerase I poison as anticancer agent

    by Biswajit Kundu, Dipayan Sarkar, Srijita Paul Chowdhuri, Sourav Pal, Subhendu K. Das, Benu Brata Das, Arindam Talukdar


  • Open Access

    SCAN1-TDP1 trapping on mitochondrial DNA promotes mitochondrial dysfunction and mitophagy

    by Arijit Ghosh, Sangheeta Bhattacharjee, Srijita Paul Chowdhuri, Abhik Mallick, Ishita Rehman, Sudipta Basu, Benu Brata Das

    A homozygous mutation of human tyrosyl-DNA phosphodiesterase 1 (TDP1) causes the neurodegenerative syndrome, spinocerebellar ataxia with axonal neuropathy (SCAN1). TDP1 hydrolyzes the phosphodiester bond between DNA 3′-end and a tyrosyl moiety within trapped topoisomerase I (Top1)-DNA covalent complexes (Top1cc). TDP1 is critical for mitochondrial DNA (mtDNA) repair; however, the role of mitochondria remains largely unknown for the etiology of SCAN1. We demonstrate that mitochondria in cells expressing SCAN1-TDP1 (TDP1H493R) are selectively trapped on mtDNA in the regulatory non-coding region and promoter sequences. Trapped TDP1H493R-mtDNA complexes were markedly increased in the presence of the Top1 poison (mito-SN38) when targeted selectively into mitochondria in nanoparticles. TDP1H493R-trapping accumulates mtDNA damage and triggers Drp1-mediated mitochondrial fission, which blocks mitobiogenesis. TDP1H493R prompts PTEN-induced kinase 1–dependent mitophagy to eliminate dysfunctional mitochondria. SCAN1-TDP1 in mitochondria creates a pathological state that allows neurons to turn on mitophagy to rescue fit mitochondria as a mechanism of survival.


  • Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity

    by Biswajit Kundu, Subhendu Kumar Das, Srijita Paul Chowdhuri, Sourav Pal, Dipayan Sarkar, Arijit Ghosh, Ayan Mukherjee, Debomita Bhattacharya, Benu Brata Das, Arindam Talukdar

    To overcome chemical limitations of camptothecin (CPT), we report design, synthesis and validation of quinoline based novel class of topoisomerase I (Top1) inhibitors and establish compound 28 (N-(3-(1H-imidazol-1-yl)propyl)-6-(4-methoxyphenyl)-3-(1,3,4-oxadiazol-2-yl)quinolin-4-amine) exhibits the highest potency in inhibiting human Top1 activity with a IC50 value of 29 nM. Compound 28 traps Top1-DNA cleavage complexes (Top1cc) both in the in vitro cleavage assays and in live cells. Point mutation of Top1-N722S fails to trap compound 28-induced Top1cc due to its inability to make hydrogen bond with compound 28. Unlike CPT, compound 28 shows excellent plasma serum stability and is not a substrate of P-glycoprotein 1 (permeability glycoprotein; Pgp) advancing its potential anticancer activity. Finally, we provide evidence that compound 28 overcomes the chemical instability of CPT in human breast adenocarcinoma cells through generation of persistent and less reversible Top1cc-induced DNA double strand breaks as detected by gamma-H2AX foci immunostaining after 5h of drug removal.


  • A novel metallogel based approach to synthesize (Mn, Cu) doped ZnS quantum dots and labeling of MCF-7 cancer cells

    by Soumya Bhowal, Arijit Ghosh, Srijita Paul Chowdhuri, Raju Mondal, Benu Brata Das

    The present study aims to formulate a common synthetic strategy for preparing quantum dots (QDs) in a greener way by using combination of popular methods, viz. a colloidal method with suitable capping agent and low molecular weight gel based synthesis. Pyridine dicarboxylic acid (PDC) in presence of AlCl3 forms a stable metallogel, which serves as an excellent medium for selective ZnS QD synthesis. The aromatic pyridine moiety, well known for being a capping agent, indeed plays its part in the run up to QD synthesis. To the best of our knowledge, this is the first example of a metallogel based doped ZnS QD synthesis. Altering the doping material and its composition changes the properties of the QDs, but herein we also tried to establish how these changes affect the gel morphology and stability of both gel and QDs. We further demonstrate, by using live cell confocal microscopy, the delivery of QDs Cu ZnS and MnZnS nanomaterials in the nucleus and the cytoplasm of human breast cancer cells (MCF7), implicating the use of metallogel based QDs for bio-imaging and bio-labeling.


  • Open Access

    Neutral Porphyrin Derivative Exerts Anticancer Activity by Targeting Cellular Topoisomerase I (Top1) and Promotes Apoptotic Cell Death without Stabilizing Top1-DNA Cleavage Complexes

    by Subhendu Kumar Das, Arijit Ghosh, Srijita Paul Chowdhuri, Nyancy Halder, Ishita Rehman, Souvik Sengupta, Krushna Chandra Sahoo, Harapriya Rath, Benu Brata Das

    Camptothecin (CPT) selectively traps topoisomerase 1-DNA cleavable complexes (Top1cc) to promote anticancer activity. Here, we report the design, synthesis of a new class of neutral porphyrin derivative 5,10-bis(4-carboxyphenyl)-15, 20-bis(4-dimethylaminophenyl)-porphyrin (compound 8), as a potent catalytic inhibitor of human Top1. In contrast to CPT, compound 8 reversibly binds with the free enzyme and inhibits the formation of Top1cc and promotes reversal of the preformed Top1cc with CPT. Compound 8 induced inhibition of Top1cc formation in live cells was substantiated by fluorescence recovery after photobleaching (FRAP) assays. We established that MCF7 cells treated with compound 8 triggers proteasome-mediated Top1 degradation, accumulates higher levels of reactive oxygen species (ROS), PARP1 cleavage, oxidative DNA fragmentation and stimulates apoptotic cell death without stabilizing apoptotic Top1-DNA cleavage complexes. Finally, compound 8 shows anticancer activity by targeting cellular Top1 and preventing the enzyme from directly participating in the apoptotic process.